The Fed kept rates unchanged for now, a move that was widely expected. It did note, though, that “uncertainty around the ...

In a report released today, Asthika Goonewardene from Truist Financial maintained a Hold rating on Gilead Sciences (GILD – Research Report).

Stocks rose on Wednesday after the Federal Reserve indicated two rate cuts are still in its forecast for 2025.

Gilead Sciences, Inc. (GILD) is currently at $106.30, down $3.94 or 3.57% --Would be lowest close since Feb. 18, 2025, when it closed at $105.25 --On pace for largest percent decrease since Nov. 15, ...

The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.

Gilead Sciences Inc. closed 8.11% short of its 52-week high of $119.96, which the company achieved on March 10th.

DelveInsight recently conducted an in-depth MASH Market Size and Share Assessment to help a pharmaceutical client understand the ...

Gilead Sciences, Inc. today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference on Retroviruses ...

Gilead Sciences, Inc. today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company's injectable HIV-1 capsid inhibitor, ...

WeDriveU Customers Named Best Workplaces and Best Universities for Commuters in 2025 WeDriveU logo Annual award program honors emplo ...

because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. Gilead Sciences has a better P/E ...